Ophthalmology Articles
Chairman sees long-term Vision Group model working well
WHEN Vision Group floated five years ago, investors fell over themselves to get a bit of the action.
It Looks Like A Vision Splendid, So Why Has The Share Price Gone On The Blink?
"I've got no idea," says the ophthalmology company's chief executive. "You tell me why we're so undervalued." Christopher Webb reports.
One-eyed Hawk Kept Sight Of The Main Game
JOHN LLEWELLYN COLVIN, AM EDUCATOR, INNOVATOR IN OPHTHALMOLOGY 14-1-1929 - 6-8-2005
Regenera Drug Makes Eye Contact With Us
DRUG developer Regenera will start receiving royalty income from next year after signing a licensing deal worth up to $US140 million ($A183 million) with a leading US ophthalmology company.
A Future Focused On Ophthalmology
Dr Anna Pang, currently completing her intern year at the Austin Hospital, wants to pursue a career in ophthalmology. She speaks to ophthalmic surgeon Dr Rick Wolfe, the director of Vista Laser Eye Clinics, about how to get there.
